Policy Brief: Dr. Adam Leventhal Discusses the FDA Authorization of the Marketing of Three New E-Cigarette Products
Listen now
Description
On this new Addiction Psychologist segment, we talk to experts about new policy developments to get a better understanding of the implications for our work, our clients, and our personal lives. On this episode, we talk with Dr. Adam Leventhal about the October 12, 2021 announcement that the FDA has authorized the marketing of three new tobacco products, marking the first set of electronic nicotine delivery system (ENDS) products ever to be authorized by the FDA through the Premarket Tobacco Product Application (PMTA) pathway. Dr. Adam Leventhal is a Professor in the Department of Preventive Medicine and Psychology in the Keck School of Medicine at the University of Southern California and a member of the Tobacco Products Scientific Advisory Committee for the Food and Drug Administration. You can read the full FDA press release here. In the days after the recording of this episode, the FDA made a similar announcement authorizing several oral tobacco products, suggesting that authorizations may occur at a rapid pace in the coming weeks. 
More Episodes
People attempting recovery from addiction are best served when recovery can be achieved through multiple, diverse, pathways that fit their needs and recovery goals. Although the most commonly used recovery support service is Alcoholics Anonymous (or a similar Anonymous affiliated group), some...
Published 04/09/24
Published 04/09/24
In the past few years, a novel adulterant, Xylazine, has emerged in the illicit opioid drug supply. Between 2020 and 2021, there was a more than 1000% increase in xylazine-positive overdose mortalities in the United States from 2020 to 2021. What is Xylazine? How does it work? Why has it emerged...
Published 03/11/24